References
- Dillman R O, Herndon J E, Seagren S L. Improved survival in stage III non-small cell lung cancer: seven-year follow-up of Cancer and Leukemia group B (CALGB) 8433 trial. J Natl Cancer Inst 1996; 88: 1210–1215
- Sause W T, Scott C, Taylor S. Radiation Therapy Oncology Group (RTOG) 88–08 and Eastern Cooperative Oncology Group (ECOG) 4588: preliminary results of a phase III trial in regionally advanced unresectable non-small-cell lung cancer. J Natl Cancer Inst 1995; 87: 198–205
- American Society of Clinical Oncology. Clinical practice guidelines for the treatment of unresectable non-small-cell lung cancer. J Clin Oncol 1997; 15: 2996–3018
- Ratain M J, Vogelzang N J, Sinkule J A. Interpatient and intrapa-tient variability in vinblastine pharmacokinetics. Clin Pharmacol Ther 1987; 4: 16–67
- Owellen R J, Hartke C A, Hains F O. Pharmacokinetics and metabolism of vinblastine in humans. Cancer Res 1977; 37: 2597–2602
- Nelson R L. The comparative clinical pharmacology and pharmacokinetics of vindesine, vincristine and vinblastine in human patients with cancer. Med Pediatr Oncol 1982; 10: 115–127
- Lu K, Yap H, Loo T L. Clinical pharmacokinetics of vinblastine by continuous infusion. Cancer Res 1983; 43: 1405–1408
- Linn S C, Van Kalken C K, Van Tellingen O. Clinical and pharmacological study of multidrug resistance reversal with vinblastine and bepridil. J Clin Oncol 1994; 12: 812–819
- Ratain M J, Vogelzang N J. Limited sampling model for vinblastine pharmacokinetics. Cancer Treat Rep 1987; 71: 935–939
- Rowinsky E K, Citardi M J, Noe D A. Sequence-dependent cytotoxic effects due to combinations of cisplatin and the antimi-crotubule agents taxol and vincristine. J Cancer Res Clin Oncol 1993; 119: 727–733
- Rowinsky E K, Gilbert M R, McGuire W P. Sequences of taxol and cisplatin: a phase I and pharmacologic study. J Clin Oncol 1991; 9: 1692–1703
- Millross C G, Peters L J, Hunter N R. Sequence-dependent antiturnour activity of paclitaxel (taxol) and cisplatin in vivo. Int J Cancer 1995; 62: 599–604
- Jekunen A P, Christen R D, Shalinsky D R. Synergistic interaction between cisplatin and taxol in human ovarian carcinoma cells in vitro. Br J Cancer 1994; 69: 299–306
- Christen R D, Jekunen A P, Jones J A. In vitro modulation of cisplatin accumulation in human ovarian carcinoma cells by pharmacologic alteration of microtubules. J Clin Invest 1993; 92: 431–440
- Teak J D, Clough J M, Marks V. Radioimmunoassay of vinblastine and vincristine. Br J Clin Pharmacol 1977; 4: 169–172
- Rowland M, Tozer T N. Clinical Pharmacokinetics Concepts and Applications, 2nd ed. Lea and Febiger, Philadelphia 1989; 233
- Ritschel W A. Graphic Approach to Clinical Pharmacokinetics. JR Prous, Barcelona 1983; 39
- Zhou-Pan X, Seree E, Zhou X. Involvement of human liver cytochrome p450 3A in vinblastine metabolism: drug interactions. Cancer Res 1993; 53: 5121–5126
- Leblanc G A, Sundseth S S, Weber G F. Platinum anticancer drugs modulate P-450 mRNA levels and differentially alter hepatic drug and steroid hormone metabolism in male and female rats. Cancer Res 1992; 52: 540–547
- Borch R F. The platinum anti-tumour drugs. Metabolism and Action of Anti-Cancer Drugs, G Powis, RA Prough. Taylor and Francis, London 1987; 163–193
- Ratain M J, Vogelzang N J. Phase I and pharmacological study of vinblastine by prolonged continuous infusion. Cancer Res 1986; 46: 4827–4830
- Rahmani R, Zhou X. Pharmacokinetics and metabolism of vinca alkaloids. Cancer Surv 1993; 17: 269–281